ArticleSleep & breathing = Schlaf & Atmung2026
Prevalence and impact of sleep disorders in patients with hereditary angioedema: A multicenter cross-sectional study in Latin America.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHereditary angioedema (HAE) is a rare disease characterized by recurrent swelling episodes that may affect sleep and quality of life. Because data on sleep disorders in Latin American patients with HAE are limited, we assessed their prevalence and clinical correlates using structured sleep and HAE patient-reported outcome measures.
objectiveTo assess the prevalence/impact of sleep disorders in HAE patients using validated tools.
methodsThis cross-sectional, multicenter online survey included adult patients (> = 18 years) with clinician-confirmed HAE from 13 reference centers in five Latin American countries. Data were collected between August and December 2023. Sleep was assessed using the Global Sleep Assessment Questionnaire (GSAQ), SATED scale, and STOP-Bang; HAE was assessed using the Hereditary Angioedema Activity Score (HAE-AS), Angioedema Control Test (AECT), and Angioedema Quality of Life questionnaire (AE-QoL). Logistic regression models were adjusted for age, sex, and BMI.
resultsThe final analytic sample included 139 participants. Most patients had HAE-C1INH type 1 (64.0%) and were female (68.4%). Only 6.5% had good sleep health, and the mean SATED score was 5.46 (1.87). Insomnia was reported by 54.0% of participants, and 34.5% had STOP-Bang moderate-to-high OSA risk. In age-, sex-, and BMI-adjusted models, severe HAE activity was associated with higher odds of insomnia (OR = 2.62, 95% CI: 1.28-5.35, P = 0.008), RLS/PLMD (OR = 5.85, 95% CI: 1.59-21.62, P = 0.008), and STOP-Bang moderate-to-high OSA risk (OR = 2.37, 95% CI: 1.01-5.55, P = 0.047). Higher AE-QoL fatigue/mood and fears/shame scores were associated with several sleep outcomes. AECT control status did not show a consistent independent association after simultaneous adjustment.
conclusionIn this exploratory cross-sectional study, HAE activity and quality-of-life impairment were associated with several sleep outcomes. Targeted sleep screening may be useful in HAE care pathways if these associations are confirmed in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.